Company intelligence / Profile preview

PreMD

Toronto, Ontario, Canadaepremd.com ↗

Ownership: Private
Development stage: Commercial

Overview

PreMD developed rapid, non-invasive diagnostic tests for early detection of life-threatening diseases. Its lead product was the PREVU skin cholesterol test for cardiovascular risk assessment. The company also developed non-invasive tests for colorectal, lung, and breast cancers. PREVU was cleared in Canada and CE marked but faced regulatory hurdles with the FDA regarding expanded indications. Cancer diagnostics were under clinical development as of late 2008.

Therapeutic areas: OncologyCardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Metabolite Diagnostics

Drug pipeline

3 assets

PREVU(x)

Commercial

Indications: Cardiovascular disease

2 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca Pharmaceuticals LP licensed PREVU technology for potential US marketing/distribution in July 2007

Beyond the preview

Go deeper on PreMD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreMD.

Explore the full profile